文献速递膀胱癌与上尿路尿路上皮癌前列腺癌肾癌与肾肿瘤

推迟泌尿生殖系统肿瘤治疗的风险:协作综述助力COVID-19大流行期间的分诊与管理

Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.
PubMed 文献 · Eur Urol · 2020-05-03

该协作综述基于截至2020年4月2日的文献,评估了COVID-19大流行期间延迟治疗各类泌尿生殖系统肿瘤的风险,以协助分诊。综述指出低级别非肌层浸润性膀胱癌延迟3-6个月影响不大,而肌层浸润性膀胱癌根治性膀胱切除延迟超过12周有疾病进展风险;低危前列腺癌可主动监测,中高危前列腺癌可推迟3-6个月;T1/T2肾 masses可安全推迟,局部晚期(≥T3)应尽快治疗;上尿路尿路上皮癌高级别延迟12周行肾输尿管切除术不增加不良生存;睾丸癌和阴茎癌应优先治疗。

要点

  • 肌层浸润性膀胱癌根治性膀胱切除延迟超过12周有进展风险,应优先手术或放化疗。
  • 中高危前列腺癌治疗可推迟3-6个月而不影响结局,低危前列腺癌可行主动监测。
  • T1/T2肾 masses可安全推迟干预,局部晚期(≥T3)肾肿瘤应尽快治疗。

核心结论

  • 患者和临床医生应权衡延迟肿瘤干预的肿瘤学风险与COVID-19对患者、医护人员和医疗系统的风险。

研究设计与样本

  • 协作综述,检索截至2020年4月2日发表的文献。

主要发现

  • 低级别非肌层浸润性膀胱癌患者不太可能因延迟3-6个月而受损。
  • 肌层浸润性膀胱癌患者有疾病进展风险,根治性膀胱切除延迟超过诊断或完成新辅助化疗后12周。
  • 低危前列腺癌应使用主动监测,大多数中危和高危前列腺癌患者治疗可推迟3-6个月而不改变结局。
  • T1/T2肾 masses干预可安全推迟,而局部晚期肾肿瘤(≥T3)应尽快治疗。
  • 上尿路尿路上皮癌高级别疾病延迟12周行肾输尿管切除术与不良生存结局无关。

关键数值与推荐

  • 肌层浸润性膀胱癌:根治性膀胱切除延迟超过12周(从诊断或完成新辅助化疗起)有进展风险。
  • 低危前列腺癌:主动监测;中危和高危前列腺癌:治疗可推迟3-6个月。
  • 肾 masses:T1/T2可安全推迟干预;局部晚期(≥T3)应尽快治疗。
  • 上尿路尿路上皮癌高级别:延迟12周行肾输尿管切除术不增加不良生存风险。
  • 阴茎癌:腹股沟淋巴结清扫延迟≥3个月与不良结局相关。

临床怎么用

  • 根据肿瘤类型和风险分层进行分诊,优先治疗肌层浸润性膀胱癌、局部晚期肾肿瘤、睾丸癌和阴茎癌患者。
  • 低级别非肌层浸润性膀胱癌、低危前列腺癌和T1/T2肾 masses患者可考虑推迟治疗。

局限性

  • 许多癌症的数据缺乏且方法学存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers. OBJECTIVE: To provide a contemporary picture of the risks from delayed treatment for urologic cancers to assist with triage. EVIDENCE ACQUISITION: A collaborative review using literature published as of April 2, 2020. EVIDENCE SYNTHESIS: Patients with low-grade non-muscle-invasive bladder cancer are unlikely to suffer from a 3-6-month delay. Patients with muscle-invasive bladder cancer are at risk of disease progression, with radical cystectomy delays beyond 12 wk from diagnosis or completion of neoadjuvant chemotherapy. Prioritization of these patients for surgery or management with radiochemotherapy is encouraged. Active surveillance should be used for low-risk prostate cancer (PCa). Treatment of most patients with intermediate- and high-risk PCa can be deferred 3-6 mo without change in outcomes. The same may be true for cancers with the highest risk of progression. With radiotherapy, neoadjuvant androgen deprivation therapy (ADT) is the standard of care. For surgery, although the added value of neoadjuvant ADT is questionable, it may be considered if a patient is interested in such an approach. Intervention may be safely deferred for T1/T2 renal masses, while locally advanced renal tumors (≥T3) should be treated expeditiously. Patients with metastatic renal cancer may consider vascular endothelial growth factor targeted therapy over immunotherapy. Risks for delay in the treatment of upper tract urothelial cancer depend on grade and stage. For patients with high-grade disease, delays of 12 wk in nephroureterectomy are not associated with adverse survival outcomes. Expert guidance recommends expedient local treatment of testis cancer. In penile cancer, adverse outcomes have been observed with delays of ≥3 mo before inguinal lymphadenectomy. Limitations include a paucity of data and methodologic variations for many cancers. CONCLUSIONS: Patients and clinicians should consider the oncologic risk of delayed cancer intervention versus the risks of COVID-19 to the patient, treating health care professionals, and the health care system. PATIENT SUMMARY: The coronavirus disease 2019 pandemic has led to delays in the treatment of patients with urologic malignancies. Based on a review of the literature, patients with high-grade urothelial carcinoma, advanced kidney cancer, testicular cancer, and penile cancer should be prioritized for treatment during these challenging times.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Wallis CJD, Novara G, Marandino L, et al. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020. PMID: 32414626. doi:10.1016/j.eururo.2020.04.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。